Gunnar Folprecht

List of Publications by Citations

124 papers	11,304 citations	37 h-index	106 g-index
130 ext. papers	13,323 ext. citations	6.6 avg, IF	5.45 L-index

#	Paper	IF	Citations
124	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *New England Journal of Medicine*, **2009**, 360, 1408-17	59.2	3065
123	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *Journal of Clinical Oncology*, **2011**, 29, 2011-9	2.2	1463
122	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncology, The*, **2010**, 11, 38-47	21.7	738
121	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet, The*, **2019**, 393, 1948-1957	40	675
120	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncology, The*, **2012**, 13, 679-87	21.7	484
119	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. *Annals of Oncology*, **2005**, 16, 1311-9	10.3	462
118	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2015**, 16, 979-89	21.7	432
117	Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. *Cancer Research*, **2011**, 71, 5670-7	10.1	294
116	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	269
115	Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. *Annals of Oncology*, **2004**, 15, 1330-8	10.3	193
114	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 862-73	21.7	190
113	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. *Annals of Oncology*, **2006**, 17, 450-6	10.3	185
112	Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. *Journal of Clinical Oncology*, **2008**, 26, 1443-51	2.2	181
111	Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). *Annals of Oncology*, **2014**, 25, 1018-25	10.3	166
110	Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *British Journal of Cancer*, **2010**, 102, 500-5	8.7	150
109	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. *Journal of Clinical Oncology*, **2019**, 37, 3212-3222	2.2	148
108	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	138

107	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 420-435	21.7	110
106	Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. *Clinical Cancer Research*, **2011**, 17, 4892-900	12.9	102
105	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. *JAMA Oncology*, **2016**, 2, 643-653	13.4	87
104	Chemotherapy in elderly patients with colorectal cancer. *Oncologist*, **2008**, 13, 390-402	5.7	82
103	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. *Annals of Oncology*, **2014**, 25, 2378-2385	10.3	72
102	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. *Annals of Oncology*, **2013**, 24, 1560-7	10.3	65
101	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. *JAMA Oncology*, **2018**, 4, 379-383	13.4	64
100	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. *European Journal of Cancer*, **2016**, 63, 11-24	7.5	63
99	Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. *Cancer Immunology, Immunotherapy*, **2006**, 55, 268-76	7.4	57
98	Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *BMC Cancer*, **2011**, 11, 509	4.8	53
97	Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. *British Journal of Cancer*, **2009**, 100, 44-9	8.7	53
96	Colorectal Liver Metastases: A Critical Review of State of the Art. *Liver Cancer*, **2016**, 6, 66-71	9.1	51
95	Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. *Annals of Oncology*, **2016**, 27, 1273-9	10.3	51
94	EORTC Elderly Task Force expertsRopinion for the treatment of colon cancer in older patients. *Cancer Treatment Reviews*, **2010**, 36, 83-90	14.4	50
93	Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. *European Journal of Cancer*, **2013**, 49, 439-48	7.5	48
92	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. *Nature Communications*, **2017**, 8, 14093	17.4	47
91	Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. *European Journal of Cancer*, **2014**, 50, 1590-601	7.5	47
90	Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. *Pflugers Archiv European Journal of Physiology*, **1995**, 430, 802-7	4.6	44

89	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. *JAMA Oncology*, **2018**, 4, e173695	13.4	37
88	European perspective for effective cancer drug development. *Nature Reviews Clinical Oncology*, **2014**, 11, 492-8	19.4	36
87	Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization. *Japanese Journal of Clinical Oncology*, **2007**, 37, 942-50	2.8	36
86	The role of new agents in the treatment of colorectal cancer. *Oncology*, **2004**, 66, 1-17	3.6	33
85	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. *Oncotarget*, **2016**, 7, 44322-44329	3.3	33
84	Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients. *Annals of Oncology*, **2017**, 28, 824-830	10.3	31
83	Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. *BMC Cancer*, **2014**, 14, 521	4.8	29
82	Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. *Cancer Treatment and Research*, **2007**, 134, 425-40	3.5	29
81	Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. *British Journal of Cancer*, **2015**, 113, 1027-34	8.7	28
80	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. *European Journal of Cancer*, **2017**, 82, 16-24	7.5	28
79	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. *Cancer Discovery*, **2021**, 11, 2780-2795	24.4	24
78	Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. *Clinical Cancer Research*, **2008**, 14, 215-23	12.9	23
77	Immunolocalization of lamins and nuclear pore complex proteins by atomic force microscopy. *Pflugers Archiv European Journal of Physiology*, **1995**, 430, 795-801	4.6	23
76	Immunotherapy of Colon Cancer. *Oncology Research and Treatment*, **2018**, 41, 282-285	2.8	22
75	Metastases in the Absence of a Primary Tumor: Advances in the Diagnosis and Treatment of CUP Syndrome. *Deutsches Ärzteblatt International*, **2008**, 105, 733-40	2.5	22
74	Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. *Oncology Research and Treatment*, **2020**, 43, 628-636	2.8	22
73	O-0024 Phase 2 Randomized, Noncomparative, Open-Label Study of Aflibercept and Modified Folfox6 in the First-Line Treatment of Metastatic Colorectal Cancer (AFFIRM). *Annals of Oncology*, **2012**, 23, iv16	10.3	20
72	Bevacizumab for recurrent hemangioendothelioma. *Acta Oncologica*, **2011**, 50, 153-4	3.2	17

71	Comparison of histopathological and gene expression-based typing of cancer of unknown primary. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2010**, 456, 23-9	5.1	16
70	Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. *Clinical Colorectal Cancer*, **2016**, 15, e29-39	3.8	15
69	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. *Clinical Cancer Research*, **2018**, 24, 4745-4753	12.9	14
68	Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. *British Journal of Cancer*, **2012**, 107, 1044-50	8.7	14
67	Aldosterone activates the nuclear pore transporter in cultured kidney cells imaged with atomic force microscopy. *Pflugers Archiv European Journal of Physiology*, **1996**, 432, 831-8	4.6	14
66	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. *JAMA Oncology*, **2021**, e215445	13.4	14
65	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. *International Journal of Cancer*, **2019**, 145, 2282-2291	7.5	13
64	Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. *Annals of Oncology*, **2018**, 29, 1793-1799	10.3	13
63	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. *Experimental & Translational Stroke Medicine*, **2013**, 5, 7		13
62	Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer. *Cancer Communications*, **2019**, 39, 74	9.4	12
61	PatientsR perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population. *BMC Cancer*, **2013**, 13, 66	4.8	12
60	Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). *Pharmacogenomics Journal*, **2013**, 13, 410-6	3.5	12
59	Carcinoma of Unknown Primary - an Orphan Disease?. *Breast Care*, **2008**, 3, 164-170	2.4	12
58	Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. *OncoImmunology*, **2018**, 7, e1393133	7.2	11
57	Accomplishments in 2008 in the management of curable metastatic colorectal cancer. *Gastrointestinal Cancer Research: GCR*, **2009**, 3, S15-22		11
56	TrousseauR syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. *British Journal of Clinical Pharmacology*, **2011**, 72, 715-6	3.8	9
55	Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. *Oncology Research and Treatment*, **2009**, 32, 162-6	2.8	9
54	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). *Strahlentherapie Und Onkologie*, **2021**, 197, 19-26	4.3	8

53	Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. *Annals of Surgical Oncology*, **2020**, 27, 2389-2401	3.1	7
52	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1153-1161	4	7
51	Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting. *Nature Clinical Practice Oncology*, **2005**, 2, 578-87		7
50	Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study.. *Journal of Clinical Oncology*, **2012**, 30, 540-540	2.2	7
49	Germline genetics of cancer of unknown primary (CUP) and its specific subtypes. *Oncotarget*, **2016**, 7, 22140-9	3.3	7
48	Acute ischaemic stroke and myocardial infarction after chemotherapy with vinorelbine for non-small cell lung cancer: a case report. *Journal of Chemotherapy*, **2017**, 29, 49-53	2.3	6
47	Role of new agents in the treatment of colorectal cancer. *Surgical Oncology*, **2004**, 13, 75-81	2.5	6
46	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. *Journal of Clinical Oncology*, **2015**, 33, 3507-3507	2.2	6
45	Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.. *Journal of Clinical Oncology*, **2016**, 34, 647-647	2.2	6
44	Liver Metastases in Colorectal Cancer. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e186-92	7.1	6
43	Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc Monocytes in Rectal Cancer. *Frontiers in Immunology*, **2019**, 10, 602	8.4	5
42	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. *JCO Precision Oncology*, **2020**, 4,	3.6	4
41	Neoadjuvant chemotherapy for non-/resectable metastases. *European Journal of Cancer*, **2011**, 47 Suppl 3, S52-60	7.5	4
40	Biomarkers for therapeutic efficacy. *European Journal of Cancer, Supplement*, **2007**, 5, 129-142	1.6	4
39	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform.. *Journal of Clinical Oncology*, **2015**, 33, 575-575	2.2	4
38	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. *Journal of Clinical Oncology*, **2019**, 37, 3520-3520	2.2	4
37	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. *European Journal of Cancer*, **2021**, 144, 101-112	7.5	4
36	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.. *JCO Precision Oncology*, **2018**, 2, 1-13	3.6	4

35	Introduction: Advances in treatment of metastatic colorectal cancer. *Cancer Treatment Reviews*, **2008**, 34 Suppl 2, S1-2	14.4	3
34	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. *Journal of Clinical Oncology*, **2016**, 34, 553-553	2.2	3
33	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. *Journal of Clinical Oncology*, **2017**, 35, 3515-3515	2.2	3
32	Efficacy and safety of CetuGEX in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC): Results from the randomized phase II RESGEX study.. *Journal of Clinical Oncology* , **2018**, 36, 59-59	2.2	3
31	Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. *Cancer Treatment Reviews*, **2021**, 102, 102301	14.4	3
30	Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor. *Nuklearmedizin - NuclearMedicine*, **2017**, 56, N19-N21	1.8	2
29	Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach?. *Cancers*, **2011**, 3, 2286-301	6.6	2
28	Intravitreous bevacizumab and blood pressure: does ‘safe’ mean ‘safe enough’?. *Acta Ophthalmologica*, **2007**, 85, 573-4; author reply 574-5		2
27	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. *Journal of Clinical Oncology*, **2015**, 33, 3506-3506	2.2	2
26	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS3634-TPS3634	2.2	2
25	Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, 598-598	2.2	2
24	Preoperative chemoradiotherapy and the long-term run in curative treatment of locally advanced oesophagogastric junction adenocarcinoma: Update of the POET phase III study.. *Journal of Clinical Oncology*, **2016**, 34, 4031-4031	2.2	2
23	Paclitaxel/carboplatin with or without cetuximab for treatment of carcinoma with unknown primary (PACET-CUP): Results of a multi-center randomized phase II AIO trial.. *Journal of Clinical Oncology*, **2019**, 37, 4120-4120	2.2	2
22	Influence of the First Wave of the COVID-19 Pandemic on Cancer Care in a German Comprehensive Cancer Center. *Frontiers in Public Health*, **2021**, 9, 750479	6	2
21	Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP. *British Journal of Cancer*, **2021**, 124, 721-727	8.7	2
20	The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management. *European Journal of Cancer, Supplement*, **2012**, 10, 51-57	1.6	1
19	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. *Journal of Clinical Oncology*, **2015**, 33, TPS789-TPS789	2.2	1
18	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. *Journal of Clinical Oncology*, **2019**, 37, 571-571	2.2	1

17	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With Fusion-Positive Carcinoma Harboring the Solvent-Front Mutation. *JCO Precision Oncology*, **2021**, 5,	3.6	1
16	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. *Oncologist*, **2021**, 26, e414-e424	5.7	1
15	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. *European Journal of Cancer*, **2021**, 144, 281-290	7.5	1
14	The CIRCULATE Trial: Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (AIO-KRK-0217). *Clinical Colorectal Cancer*, **2021**,	3.8	1
13	Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3). *International Journal of Cancer*, **2021**,	7.5	1
12	Sensitive Quantification of Cell-Free Tumor DNA for Early Detection of Recurrence in Colorectal Cancer.. *Frontiers in Genetics*, **2021**, 12, 811291	4.5	0
11	CUP Therapie nach Molekularpathologie oder mit Immuntherapie. *Onkologe*, **2017**, 23, 1006-1010	0.1	
10	Cetuximab in metastatic colorectal cancer AuthorReply. *Lancet Oncology, The*, **2010**, 11, 314	21.7	
9	Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO Past, present, and future*Onkologe*, **2022**, 28, 44	0.1	
8	Place of death and chemotherapy use at the end of life in colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e23006-e23006	2.2	
7	Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. *Journal of Clinical Oncology*, **2019**, 37, e15025-e15025	2.2	
6	Is the predictive and prognostic impact of sporadic and familial microsatellite instable stage III colon cancer different? A pooled analysis of the PETACC8 and NCCTG N0147 (Alliance) trials.. *Journal of Clinical Oncology*, **2019**, 37, 3583-3583	2.2	
5	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. *Journal of Clinical Oncology*, **2014**, 32, 3549-3549	2.2	
4	Mortality from outpatients chemotherapy (CTx) in patients (pts) with solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, e17676-e17676	2.2	
3	Differences in gene-expression in mCRC tissue samples with regard to tumor location and used chemotherapeutic substances: Data of the FIRE-1 study.. *Journal of Clinical Oncology*, **2016**, 34, 562-562	2.2	
2	Biologicals for Colorectal Cancer Metastases **2009**, 1-7		
1	Chemotherapy in the Metastatic Setting **2013**, 129-139		